LCP
BLCM

Lamond Capital Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Lamond Capital Partners’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,878
Closed -$1.46M – 13
2015
Q2 		$1.46M Buy
6,878
+3,178
+86% +$779K 1.49% 11
2015
Q1 		$857K Buy
+3,700
New +$895K 0.94% 12

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lamond Capital Partners's BLCM Position: Q3 2015 in Review

Lamond Capital Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2015, closing a stake of 6,878 shares — an estimated $1.46M sold.

Lamond Capital Partners first reported a position in BLCM in Q1 2015 and held it in 2 quarters. The position peaked at $1.46M in Q2 2015. 83 funds tracked by Wall St. Rank hold BLCM as of Q3 2015.

  • Lamond Capital Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 6,878 Bellicum Pharmaceuticals, Inc. shares in Q3 2015, an estimated $1.46M.
  • Lamond Capital Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Lamond Capital Partners's Bellicum Pharmaceuticals, Inc. position peaked at $1.46M in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2015.

Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.